LIBREXIA Trial: Milvexian Fails to Reduce CV Events After ACS but Did Exhibit Anticoagulation - Medscape

LIBREXIA Trial: Milvexian Fails to Reduce CV Events After ACS but Did Exhibit Anticoagulation MedscapeFactor XIa Inhibitor Shows No Benefit After Acute Coronary Syndrome MedPage TodayLIBREXIA ACS Fails to Improve Cardiovascular Outcomes, Doesn’t Increase Bleeding Risk HCPLiveMilvexian fails to reduce cardiovascular events after acute coronary syndrome News-MedicalLIBREXIA ACS: Milvexian Fails to Reduce MACE after Acute Coronary Syndrome HCPLive